2025-06-17-Bernstein-美国生命科学工具与诊断_月度行业健康追踪（5月数据+会议要点）_22页_2mb

报告摘要

Mixed Trends in Conference Discussions (May-June 2025):
- Positive: Optimism around NIH funding cuts' reduced impact and improved US-China trade relations.
- Negative: Heightened pessimism on biotech funding, declining biotech investment, and polarized views on pharma customer demand.
- src:
  - Pharma cautiousness: Polarized opinions; some companies note customer strength, while others report ongoing caution.
  - Biotech: Sentiment increasingly negative due to weak capital markets and reduced stimulus effectiveness.
  - China: Less polarized, but short-term headwinds persist; long-term outlook uncertain.
  - Consumables: Destocking concerns ease but remain a mixed sentiment topic.

Most sector metrics show YoY declines or sequential deterioration, though a few bright spots exist:

Clinical Trial Starts: 🚀 Up 25% YoYo and 8% MoM (clinical trials).
Pharma R&D Spend: Grew 3% in Q1 2025 (25Q1) but still below long-term averages.
NIH Funding & Biosimilars: YoY declines in funding and awards, but biosimilar approvals slightly ahead YoY.
Other Metrics: Decreases YoY for drug approvals, licensing deals, biotech funding, and NIH awards.

Clinical Trials & R&D: Notable bright spot; trials increased 25% YoY and R&D spend grew slightly.
NIH Funding: YoY decline (down 8% MoM and YoY overall).
China Market: Moderated sentiment, balancing cautiousness with short-term improvements.
Biotech Investment: Continues to decline, reflecting weak funding cycles.

Mixed Signals: Sector health tracker shows improvement in some areas (China, NIH) but persistent weakness in others (biotech funding, pharma R&D).
Political & Economic Sensitivity: Outcomes depend heavily on NIH funding cycles, trade policies, and biotech investment stability.

%
For detailed metrics and company-specific trends, refer to the report's quantitative charts.
%

展开完整摘要